Determination of 1,3-ß-D-glucan in the peritoneal fluid for the diagnosis of intra-abdominal candidiasis in critically ill patients: a pilot study.

Date publication

juillet 2018

Journal

Minerva anestesiologica

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ALBUISSON Eliane

Tous les auteurs :
Novy E, Laithier FX, Machouart MC, Albuisson E, Guerci P, Losser MR

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29991219

Résumé

Decision to start an anti-fungal therapy in intra-abdominal candidiasis (IAC) is complex. Yeast culture, considered the gold standard, suffers from a delayed response time and exposes the patient to delayed introduction of anti-fungal therapy. We sought to evaluate the performance and feasibility of measuring 1,3-Beta-D-Glucan (1,3BDG) in the peritoneal fluid (PF) for the diagnosis of IAC.

Référence

Minerva Anestesiol. 2018 Jul 9;: